Floatz logo

Bxcl501

Schizophrenia

BioXcel Therapeutics IncPhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
74/ 100
Competitive Position
65/ 100

Competitive context

144 Active assets in the Schizophrenia cohort.

Asset / SponsorPhaseRating
Lurasidone
Aziende Chimiche Riunite Angelini Francesco S.p.A
Phase 4BBB
Asenapine
Noven Pharmaceuticals, Inc.
Phase 4BBB
Xanomeline
European Group for Research In Schizophrenia
Phase 4BBB
TROSPIUM
European Group for Research In Schizophrenia
Phase 4BBB
Opc-34712
Humanis Saglık Anonim Sirketi
Phase 4BBB

View all 50 →

Same molecule, other indications

Bxcl501 is also rated in:

Pain, ChronicDormant
A
Indicative ·
80 / 100
View asset →
Agitation,PsychomotorDormant
A
Indicative ·
80 / 100
View asset →
schizophreniform disorderDormant
A
Indicative ·
80 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →